ClinicalTrials.gg

Program

Bcl-2 Inhibitor TQB3909

Also written as “TQB3909 tablets”, “TQB3909 Tablets” and “TQB3909 Tablets + Azacitidine”.

In Sino Biopharmaceutical’s pipeline, BCL-2抑制剂. Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Primary Myelofibrosis · Hematologic Neoplasms · Breast Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 3, since Aug 4, 20268 company-led studies, 5 open or runningNext primary completion: Dec 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical85 open or runningphase 3since Aug 4, 2026Jul 14, 2021Dec 2030phase 3 · NCT07753369

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2021First study: phase 1 study in Advanced Malignant TumorFirst studyNCT04975204 · 126 enrolled · China
  2. Dec 7, 2022Phase 2 study in Advanced Breast CancerNCT05775575 · 65 enrolled · China
  3. Jul 17, 2023Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05959694 · 107 planned · China
  4. Nov 30, 2023Phase 1 study in Advanced Malignant NeoplasmNCT06165822 · 40 planned · China
  5. Jan 9, 2024Phase 1 study in Hematologic NeoplasmsNCT06211751 · 208 planned · China
  6. Jan 30, 2024Phase 2 study in Primary MyelofibrosisNCT06245941 · 21 enrolled · China
  7. May 21, 2025Phase 2 study in Myeloid MalignancyNCT07011186 · 138 planned · China
  8. Aug 4, 2026Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellPhase 3 reachedNCT07753369 · 128 planned · China

Ahead

  1. Dec 2030Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07753369

TargetBeta

“BCL-2抑制剂”the company's pipeline, read by Claude · source

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
venetoclaxruleAbbViephase 483
lacutoclaxruleLupeng Pharmaceuticalphase 24
surzetoclaxAbbViephase 23
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 21
surzetoclaxAbbViephase 12
FXS0683Fosun Pharmaphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07753369Leukemia, Lymphocytic, Chronic, B-Cell · China3Not yet recruitingDec 2030128
NCT07011186Myeloid Malignancy · China2RecruitingOct 2025138
NCT06245941Primary Myelofibrosis · China2TerminatedDec 30, 202521
NCT06211751Hematologic Neoplasms · China1Not yet recruitingDec 2025208
NCT06165822Advanced Malignant Neoplasm · China1Not yet recruitingJan 202440
NCT05959694Leukemia, Lymphocytic, Chronic, B-Cell · China2RecruitingDec 2025107
NCT05775575Advanced Breast Cancer · China2UNKNOWNDec 202365
NCT04975204Advanced Malignant Tumor · China1UNKNOWNDec 2022126

How it is read

Names in the registry

  • “TQB3909 tablets”, 4 entries
  • “TQB3909 Tablets”, 2 entries
  • “TQB3909 Tablets + Azacitidine”, 1 entry
  • “TQB3909 tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.